What question did this study set out to answer?

To assess the impact of benzodiazepines versus non-benzodiazepine antiseizure medications on mortality and outcomes in status epilepticus.

November 12, 2025Frontiers in NeurologyOpen Access

Benzodiazepines versus non-benzodiazepine antiseizure medications as first-line agents for status epilepticus: analysis of real word data from a 9-years prospective cohort

View Full Paper

Ask AI

Bookmark

Authors

Cohort analysis reveals first-line benzodiazepines reduce mortality in status epilepticus, suggesting effectiveness in critical care.

To assess the impact of benzodiazepines versus non-benzodiazepine antiseizure medications on mortality and outcomes in status epilepticus.
Examined a cohort of 630 patients with status epilepticus over 9 years
Utilized logistic regression for multivariate analysis
Conducted propensity-score matched analysis to account for confounding variables
30-day mortality was 25.9% for benzodiazepine and 35.3% for non-benzodiazepine groups
Multivariate analysis showed no independent association for non-benzodiazepines on 30-day mortality
Patients receiving benzodiazepines had shorter ICU stays and less intubation

Brigo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark